The sales are consistent with routine option exercises and diversification rather than coordinated negative sentiment. The dollar amount is trivial relative to company size. No immediate trading signal; monitor for recurrence or larger-scale exits.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $588.13entry
- T+1 · 8mo ago +0.71%α −2.18% · $592.29
- T+5 · 7mo ago −4.35%α −8.65% · $562.57
- T+20 · 7mo ago −3.23%α −15.83% · $569.11
- T+60 · 5mo ago −6.50%α −22.53% · $549.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four insiders at United Therapeutics sold a combined $1.18 million in stock over a one-week window, including notable open-market sales by the CEO, CFO, general counsel, and a director. The transactions follow a pattern of routine option exercises and tax-related disposals, with the largest sale coming from a director.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 65 shares for $36K on 2026-04-02 and gifted 698,384 shares in non-cash transactions on 2026-04-01
- CFO James Edgemon sold 120 shares for $66K and exercised options for 10,000 shares at $135.42
- General Counsel Paul Mahon sold 514 shares for $288K and exercised options for 8,300 shares at $146.03
- Director Christopher Causey sold 1,300 shares for $786K on 2026-03-30 at $604.64 per share
- Total open-market sales amounted to $1.18 million, representing less than 0.005% of the $24.5B market cap
Financial Impact
$1.18 million in open-market sales over 7 days, <0.005% of market cap
Risk Factors
- Perception of insider selling could weigh on sentiment short-term
- Potential misinterpretation of gift transactions as economic dispositions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1775594183032 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers